Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma	Recruiting	Phase 1 / Phase 2	2025-07-25		NCT05491083

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Adagene Inc	6
Merck Sharp & Dohme LLC	650
National University Hospital, Singapore	120

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
National University Hospital	Singapore	Singapore	46

Clinical trials